A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
NCT ID: NCT04855721
Last Updated: 2022-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
141 participants
INTERVENTIONAL
2021-05-04
2022-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 128 patients with chronic moderate-to-severe plaque psoriasis (defined as Psoriasis Area and Severity Index (PASI) ≥12 and Body Surface Area (BSA) involved ≥10%) will be randomized to four groups (three dose groups of AUR101 and one placebo group) in the ratio of 1:1:1:1.
The patients in each arm will receive AUR101 of 200 mg twice daily, 400 mg twice daily, 400 mg once daily or matching placebo for 16 weeks in a double blind, double dummy fashion. All patients will be followed up for 14 ± 2 days of their last dose for safety assessment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AUR101 400 mg PO BID
Patients will receive AUR101 / placebo in double blind, double dummy manner
AUR101
Oral ROR-gamma inverse agonist
AUR101 200 mg PO BID
Patients will receive AUR101 / placebo in double blind, double dummy manner
AUR101
Oral ROR-gamma inverse agonist
AUR101 400 mg PO QD
Patients will receive AUR101 / placebo in double blind, double dummy manner
AUR101
Oral ROR-gamma inverse agonist
Placebo
Patients will receive AUR101 / placebo in double blind, double dummy manner
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AUR101
Oral ROR-gamma inverse agonist
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Psoriasis of at least moderate severity, defined as PASI≥12 and involved BSA≥10 % at screening and Day 1
3. Static 5-point IGA modified \[mod\] 2011 scale of 3 or higher at screening and Day 1
4. Adult males or females, ≥ 18 to ≤ 70 years of age
5. Ability to communicate well with the investigator and to comply with the requirements of the entire study
6. Willingness to give written informed consent (prior to any study related procedures being performed) and ability to adhere to the study restrictions and assessments schedule
Exclusion Criteria
2. BMI \< 18 or \> 40
3. History of lack of response to ustekinumab, secukinumab or ixekizumab (or any therapeutic agent targeted to IL12, IL-17 or IL-23) at approved doses after at least 3 months of therapy
4. Current treatment or history of treatment for psoriasis with any investigational or approved IL-17, IL-12 or IL-23 antagonist biological agents (e.g. secukinumab, briakinumab, tildrakizumab, ustekinumab etc.) within 6 months prior to the first administration of study drug.
5. Current treatment or history of treatment for psoriasis with other investigational or approved biological agents (e.g. anti-TNFα inhibitors - adalimumab, etanercept, infliximab, alefacept etc.) within 3 months prior to the first administration of study drug
6. Current treatment or history of treatment for psoriasis with non-biological systemic medications or immunomodulators (including systemic steroids, apremilast, methotrexate, cyclosporine, acitretin, etc.) or phototherapy within 4 weeks prior to the first administration of study drug.
7. Treatment with medicated topical agents (having active pharmaceutical ingredient that can impact or interfere with the effect of the study drug) within 2 weeks prior to the first administration of study drug.
8. Evidence of organ dysfunction (e.g. liver dysfunction ≥ 1.5 X of ULN for ALT, AST or ALP or Total Bilirubin, or renal dysfunction of ≥ 1.5X of ULN of serum creatinine)
9. Any surgery requiring general anesthesia within 3 months prior to screening
10. History of malignancy within last 5 years except patients with non-melanoma skin cancer or carcinoma in situ of cervix who can participate in the study. Adequately treated cutaneous basal or squamous cell carcinoma are allowed.
11. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV Ab) at screening
12. Patient with known history of systemic tuberculosis or currently suspected or known to have active tuberculosis
13. Patient expected to be started on anti-tubercular therapy either for treatment or prophylaxis of tuberculosis
14. Suspected tuberculosis infection as evident from a positive QuantiFERON TB-Gold test (QFT) or Mantoux test (MT) at screening. Patients with a positive QFT or MT may participate in the study if further work up as per the opinion of the investigator (like Chest X-ray or CT scan of Chest or other locally acceptable method for diagnosing active tuberculosis) establishes that patient does not have active tuberculosis. Patients with latent tuberculosis should not be enrolled except when they are not planned to start prophylaxis for tuberculosis during the study period.
15. History of hypersensitivity or idiosyncratic reaction to any investigational ROR-gamma inhibitors or any of the excipients of study drug
16. History of alcohol or substance abuse that will affect compliance to study procedures/schedule as per Investigator opinion
17. Any previous gastrointestinal surgery or recent (within 3 months) / current history of gastrointestinal disease, that in the opinion of investigator, could impact the absorption of the study drug
18. Positive pregnancy test for women of child-bearing potential (WOCBP) at the screening or randomization visit
19. Male patients who are sexually active with WOCBP, not willing to use reliable contraception methods as mentioned in section 8.14
20. Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable contraceptive methods (hormonal contraceptive, IUD or any double combination of male or female condom, spermicidal gel, diaphragm, sponge, cervical cap). Please see section 8.14 for acceptable contraceptive practices
21. Has received any investigational biologic agents within 3 months or 5 half-lives (whichever is longer) prior to the first administration of study drug
22. Has received another new chemical entity/non-biologic investigational drug within 28 days or 5 half-lives of investigational drug (whichever is longer) prior to study day 1
23. History of other auto-immune disorders (except psoriasis and psoriatic arthritis) where treatment with systemic immunosuppressants is required
24. History of active infection and/or febrile illness within 7 days prior to Day 1. The infection adequately treated by antibiotics during the screening period as per investigator opinion will be allowed to undergo randomization, provided patient is stable for at least 7 days before randomization
25. Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of person(s) with confirmed Covid-19 infection, at screening or Day 1
26. History or presence of any major medical illness (e.g. renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, immunologic, or local active infection/infectious illness) or psychiatric disease, or clinically significant laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study, or influence the results or the patient's ability to participate in the study
27. History of any unstable cardiac (including Class III or IV congestive heart failure by New York Heart Association Criteria), respiratory, hepatic, renal or other systemic conditions within 3 months prior to first study drug administration
28. Use of herbal remedies, mega dose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of study drug
29. Patients who have received live attenuated vaccine in the 4 weeks prior to the first administration of study drug -
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aurigene Discovery Technologies Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Divyesh Mandavia, MD
Role: STUDY_DIRECTOR
Aurigene Discovery Technologies Limited
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johnson Dermatology
Fort Smith, Arkansas, United States
Northwest AR Clinical Trials Center
Rogers, Arkansas, United States
First OC Dermatology
Fountain Valley, California, United States
Dermatology Research Associates
Los Angeles, California, United States
University Clinical Trials, Inc.
San Diego, California, United States
Clinical Science Institute
Santa Monica, California, United States
Unison Clinical Trials
Sherman Oaks, California, United States
Moore Clinical Research, Inc.
Brandon, Florida, United States
Skin Research Institute
Coral Gables, Florida, United States
Accel Research Sites - Deland CRU
DeLand, Florida, United States
FXM Clinical Research Fort Lauderdale
Fort Lauderdale, Florida, United States
Direct Helpers Research Center
Hialeah, Florida, United States
Abys New Generation Research Inc.
Hialeah, Florida, United States
FXM Clinical Research Miami LLC
Miami, Florida, United States
Floridian Reserach
Miami, Florida, United States
FXM Clinical Research Miramar LLC
Miramar, Florida, United States
Lenus Research & Medical Group, LLC
Sweetwater, Florida, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Great Lakes Research Group, Inc
Bay City, Michigan, United States
Medisearch Clinical Trials
Saint Joseph, Missouri, United States
The Dermatology Specialists
New York, New York, United States
Sadick Research Group
New York, New York, United States
Paddington Testing Co, Inc
Philadelphia, Pennsylvania, United States
Dermatology Treatment & Research Center
Dallas, Texas, United States
Center for Clinical Studies Ltd., LLP.
Webster, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUR101-202
Identifier Type: -
Identifier Source: org_study_id